Amsterdam - Delayed Quote EUR
Galapagos NV (GLPG.AS)
24.40
+0.48
+(2.01%)
At close: May 16 at 5:38:37 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
288,194
275,649
239,724
241,249
234,384
Cost of Revenue
46,044
34,863
0
0
1,629
Gross Profit
242,150
240,786
239,724
241,249
483,217
Operating Expense
556,065
429,124
327,987
372,306
405,949
Operating Income
-313,915
-188,338
-88,263
-131,057
-171,565
Net Non Operating Interest Income Expense
75,789
89,458
77,636
8,709
-9,296
Other Income Expense
55,782
95,795
16,252
51,499
61,462
Pretax Income
-182,387
-3,085
5,625
-70,849
-119,402
Tax Provision
-3,049
-1,803
9,613
572
1,389
Net Income Common Stockholders
-169,541
74,082
211,697
-217,991
-103,231
Diluted NI Available to Com Stockholders
-169,541
74,082
211,697
-217,991
-103,231
Basic EPS
-2.58
--
3.21
-3.32
-1.58
Diluted EPS
-2.58
--
3.21
-3.32
-1.58
Basic Average Shares
65,893.05
--
65,884
65,659.94
65,500
Diluted Average Shares
65,893.05
--
65,884
65,659.94
65,500
Total Operating Income as Reported
-313,915
-188,338
-88,263
-131,056
-171,568
Total Expenses
602,109
463,987
327,987
372,306
405,949
Net Income from Continuing & Discontinued Operation
-169,541
74,082
211,697
-217,991
-103,231
Normalized Income
-234,187.48
-76,960.05
-16,827.08
-112,105.21
-165,658.26
Interest Income
76,630
89,773
79,608
18,094
2,865
Interest Expense
--
911
1,770
9,155
11,592
Net Interest Income
75,789
89,458
77,636
8,709
-9,296
EBIT
-127,751
-2,174
7,395
-61,694
-107,810
EBITDA
-127,751
43,325
51,037
3,872
-73,174
Reconciled Cost of Revenue
46,044
2,536
0
0
1,629
Reconciled Depreciation
--
45,499
43,642
65,566
34,636
Net Income from Continuing Operation Net Minority Interest
-179,338
-1,282
-3,988
-71,421
-120,791
Total Unusual Items Excluding Goodwill
55,782
95,795
16,252
51,499
61,462
Total Unusual Items
55,782
95,795
16,252
51,499
61,462
Normalized EBITDA
-183,533
-52,470
34,785
-47,627
-134,636
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
932.52
20,116.95
3,412.92
10,814.79
16,594.74
12/31/2021 - 5/6/2005
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
HLVX HilleVax, Inc.
1.9700
+0.51%
PHARM.AS Pharming Group N.V.
0.8545
+2.83%
BOLT Bolt Biotherapeutics, Inc.
0.2930
-7.57%
PRTC.L PureTech Health plc
130.80
+2.19%
CRGX CARGO Therapeutics, Inc.
4.1200
+3.26%
RPTX Repare Therapeutics Inc.
1.3400
+0.75%
ASMB Assembly Biosciences, Inc.
13.42
+7.36%
ANTX AN2 Therapeutics, Inc.
1.2100
-1.63%
SEER Seer, Inc.
2.0700
-0.48%
SPRO Spero Therapeutics, Inc.
0.6510
-0.03%